Adverse drug reaction: pomalidomide-induced liver injury

Adverse drug reaction: pomalidomide-induced liver injury

Survival after multiple myeloma has improved with the use of immunomodulatory drugs--thalidomide, lenalidomide, and pomalidomide. Pomalidomide, the latest immunomodulatory drug to be approved by the US Food and Drug Administration, was developed by modifying thalidomide's chemical structure to...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) Vol. 383; no. 9935; pp. 2125 - 2126
Main Authors: Veluswamy, Rajwanth R, Ward, Stephen C, Yum, Kendra, Abramovitz, Rebecca B, Isola, Luis M, Jagannath, Sundar, Parekh, Samir
Format: Journal Article
Language:English
Published: England Elsevier Ltd 21-06-2014
Elsevier Limited
Subjects:
Chemical and Drug Induced Liver Injury - etiology
Chemotherapy
Drug dosages
Hepatotoxicity
Humans
Internal Medicine
Liver
Male
Middle Aged
Multiple myeloma
Multiple Myeloma - therapy
Side effects
Stem Cell Transplantation
Stem cells
Thalidomide - adverse effects
Thalidomide - analogs & derivatives
Transplants & implants
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Survival after multiple myeloma has improved with the use of immunomodulatory drugs--thalidomide, lenalidomide, and pomalidomide. Pomalidomide, the latest immunomodulatory drug to be approved by the US Food and Drug Administration, was developed by modifying thalidomide's chemical structure to increase potency and improve safety. Pomalidomide undergoes extensive cytochrome P450-mediated metabolism and has a toxicity profile mainly characterised by myelosuppression. Here, we discuss the first case of pomalidomide-induced hepatotoxicity reported under post-marketing surveillance.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(14)61030-8